论文部分内容阅读
目的探讨非ST段抬高型心肌梗死(NSTEMI)合并高血压、糖尿病经皮冠状动脉腔内介入(PCI)治疗时机。方法选择95例行PCI治疗的NSTEMI患者,合并高血压53例,其中早期行PCI治疗28例,择期行PCI治疗25例;合并糖尿病42例,其中早期行PCI治疗22例,择期行PCI治疗20例。比较早期与择期PCI治疗患者住院期间主要不良心脏事件及随访6个月反复心绞痛症状、再发心肌梗死、冠脉血运重建、心衰等情况。结果合并高血压的NSTEMI患者早期行PCI近期预后及随访6个月的预后好于择期行PCI治疗;合并糖尿病的NSTEMI患者早期行PCI治疗近期预后较择期PCI治疗预后差。结论对于合并高血压病的NSTEMI患者应早期积极行PCI治疗,合并糖尿病的NSTEMI患者择期PCI治疗更安全可靠。
Objective To investigate the timing of percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by hypertension and diabetes mellitus. Methods Ninety-five patients with NSTEMI undergoing PCI were enrolled in this study. Totally 53 cases were complicated with hypertension. Among them, 28 cases were treated with PCI in the early stage and 25 cases were treated with PCI in the elective period. Among them, 42 cases were complicated with diabetes mellitus, 22 cases were treated with PCI in the early stage, example. Compared with the primary adverse cardiac events during hospitalization and the recurrence of angina pectoris at 6 months after PCI, the incidence of recurrent myocardial infarction, coronary revascularization and heart failure were compared. Results The early prognosis of NSTEMI patients with early hypertension and early follow-up of 6 months was better than that of elective PCI. NSTEMI patients with diabetes mellitus had less immediate prognosis than PCI patients with early PCI. Conclusion NSTEMI patients with hypertension should be actively treated with PCI in the early stage, and patients with NSTEMI with diabetes should be treated with elective PCI more safely and reliably.